Search Browse Earnings

ZyVersa Therapeutics, Inc.

OTC:ZVSA

Pharmaceutical Preparations·WESTON, FL

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Glover Stephen C.

CFO

Wolfe Peter

Revenue

—

Adj. EBITDA

-$107.7M

FY 2024

Net Income

-$98.3M

FY 2024

EPS (Diluted)

-$1089.70

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$928,389

FY 2021

Total Debt

—

Net Cash

$928,389

Enterprise Value

—

Debt / EBITDA

0.0x

FY 2024

EV / EBITDA

—

Employees

—